Aurobindo Pharma Limited (NSE: AUROPHARMA)
India
· Delayed Price · Currency is INR
1,246.00
+10.60 (0.86%)
Nov 19, 2024, 3:30 PM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 77.96B INR in the quarter ending September 30, 2024, with 7.99% growth. This brings the company's revenue in the last twelve months to 302.95B, up 12.41% year-over-year. In the fiscal year ending March 31, 2024, Aurobindo Pharma had annual revenue of 290.02B with 16.68% growth.
Revenue (ttm)
302.95B
Revenue Growth
+12.41%
P/S Ratio
2.35
Revenue / Employee
11.65M
Employees
26,015
Market Cap
708.58B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
Mar 31, 2020 | 230.99B | 35.35B | 18.07% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAurobindo Pharma News
- 9 days ago - Q2 2025 Aurobindo Pharma Ltd Earnings Call Transcript - GuruFocus
- 11 days ago - Stocks to watch today: Divi’s Laboratories, JSW Steel, LIC, Biocon in focus; Asian Paints, Tata Motors, Aurobindo Pharma, Ola Electric under pressure - Business Upturn
- 12 days ago - Aurobindo Pharma Q2 net profit rises 9% - The Times of India
- 12 days ago - Aurobindo Pharma Q2 FY25 Results: Revenue at ₹7,796.07 crore, up 8.9% YoY; Profit at ₹816.95 crore, up 8.6% YoY - Business Upturn
- 16 days ago - Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally - Business Upturn
- 18 days ago - Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade - Business Upturn
- 20 days ago - Quant Active Fund sees 36.74% returns in last year, top holdings in Reliance Industries & Aurobindo Pharma - Business Upturn
- 21 days ago - Quant Mid Cap Fund sees 44.61% returns in last year, top holdings in Reliance Industries & Aurobindo Pharma - Business Upturn